BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 23664448)

  • 1. Clinical perspective of afatinib in non-small cell lung cancer.
    Chen X; Zhu Q; Zhu L; Pei D; Liu Y; Yin Y; Schuler M; Shu Y
    Lung Cancer; 2013 Aug; 81(2):155-61. PubMed ID: 23664448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
    Lee Y; Wang Y; James M; Jeong JH; You M
    Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
    Metro G; Crinò L
    Expert Rev Anticancer Ther; 2011 May; 11(5):673-82. PubMed ID: 21554040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib and lung cancer.
    Jain P; Khanal R; Sharma A; Yan F; Sharma N
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1391-406. PubMed ID: 25417728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
    Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
    Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
    Peters S; Zimmermann S; Adjei AA
    Cancer Treat Rev; 2014 Sep; 40(8):917-26. PubMed ID: 25027951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer.
    Bowles DW; Weickhardt A; Jimeno A
    Drugs Today (Barc); 2013 Sep; 49(9):523-35. PubMed ID: 24086949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
    Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
    Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.
    Zhang S; Zheng X; Huang H; Wu K; Wang B; Chen X; Ma S
    Oncotarget; 2015 Mar; 6(8):5832-45. PubMed ID: 25714021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
    Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
    Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
    van der Wekken AJ; Kuiper JL; Saber A; Terpstra MM; Wei J; Hiltermann TJN; Thunnissen E; Heideman DAM; Timens W; Schuuring E; Kok K; Smit EF; van den Berg A; Groen HJM
    PLoS One; 2017; 12(8):e0182885. PubMed ID: 28854272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance.
    He J; Tan W; Tang X; Ma J
    Pathol Oncol Res; 2017 Apr; 23(2):307-315. PubMed ID: 27511219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer.
    Köhler J; Schuler M
    Future Oncol; 2014 Mar; 10(4):533-40. PubMed ID: 24754585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
    Reguart N; Remon J
    Future Oncol; 2015; 11(8):1245-57. PubMed ID: 25629371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
    Liao BC; Lin CC; Yang JC
    Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.